4.6 Article

with type 2 diabetes mellitus

期刊

DIABETES & METABOLISM
卷 49, 期 1, 页码 -

出版社

MASSON EDITEUR
DOI: 10.1016/j.diabet.2022.101393

关键词

H1-Antihistamines; Hepatocellular Carcinoma; incidence rate ratio; Type 2 Diabetes Mellitus; dose -dependent

向作者/读者索取更多资源

This study investigated the association between H1-antihistamine use and hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B or C virus infection. The results showed that the use of antihistamines significantly reduced the risk of HCC in these patients, and a dose-response relationship was observed.
Purpose: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Methods: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association. Results: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively). Conclusion: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据